ARCEL GULAPA: Open Payments
NPI 1902203359 · ANAHEIM, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,143 in 41 payments from 13 companies in 2025. Trend: 2023 $0 · 2024 $333 · 2025 $1,143
Food & beverage: $1,143
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 12 | $351 |
| AstraZeneca Pharmaceuticals LP | 4 | $272 |
| Bayer Healthcare Pharmaceuticals Inc. | 5 | $110 |
| Lilly USA, LLC | 5 | $102 |
| Amgen Inc. | 4 | $67 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $63 |
| GlaxoSmithKline, LLC. | 2 | $54 |
| Sumitomo Pharma America, Inc. | 1 | $27 |
| Corcept Therapeutics | 1 | $22 |
| PFIZER INC. | 1 | $20 |
Products named: Wegovy, AIRSUPRA, Ozempic, BREZTRI, Kerendia, MOUNJARO, RELISTOR, REPATHA.
Industry payments across CA — which companies pay providers there.
